Introduction
============

Although melanoma comprises 5% of all skin-related tumors, it is responsible for 75% of the deaths caused by this type of cancer. Although significant progress has been made in the last decade and the number of cases has significantly decreased, the overall mortality rate has remained steady. New treatment strategies based on BRAF inhibitors or CTLA-4 blocking antibodies have provided only slight benefit to patients with stage IV melanoma and melanoma metastases. This moderate success provides the rationale to continue research on expanding therapies focusing on cancer biology and targeting molecular pathways crucial for proliferation, metastasis and respond to treatment ([@b1-or-40-01-0123]--[@b3-or-40-01-0123]).

DNA synthesis and repair require coordinated deoxyribonucleoside triphosphate (dNTP) supply as basic building blocks. Impaired balance of the dNTP pool affects S phase duration time, DNA synthesis fidelity, as well as the ability and effectiveness of DNA repair. Loss of control over these processes can also trigger genome instability and may initiate cancerogenesis. The increased demand for deoxyribonucleotides is serviced by upregulation of ribonucleotide reductase (RNR), which reduces the 2′ carbon of a ribonucleoside diphosphate and has been considered as the rate-limiting step in dNTP production. RNR as a heterodimeric protein consists of three subunits -- one ribonucleotide reductase family member 1 (RRM1) and two molecules of RRM2. While RRM1 expression is constant throughout the cell cycle, the expression of RRM2 fluctuates and peaks at S phase, when the need for nucleotide synthesis is the highest. The degradation of RRM2 occurs in late G2 phase of the cell cycle in the nucleus and is controlled by Skp, Cullin, F-box containing (SCF)^cyclin\ F^ ubiquitin ligase complex. The SCF complex is composed of three proteins: Skp1 and Cul1, which provide a scaffold, and F-box protein, which is responsible for target recognition ([@b4-or-40-01-0123]).

Cyclin F, like other cyclins, has both cyclin and F-box domains, but it does not bind or activate any known cyclin-dependent kinase (CDK). The expression profile of cyclin F is similar to cyclin A and fluctuates throughout the cell cycle. At the protein level, cyclin F appears in the S phase, peaks before M phase, and then its expression decreases dramatically. It is clearly visible that changes in the expression of cyclin F negatively correlates with the RRM2 level, which may suggest their cooperation in the axis, important for genome stability and DNA repair ([@b5-or-40-01-0123]). As it has been suggested, overexpression of RRM2 is associated with poorer patient prognosis in melanoma and many other cancers. Furthermore, cells with high content of RRM2 are characterized by much more effective DNA repair systems which impair the effectiveness of therapy ([@b6-or-40-01-0123]--[@b9-or-40-01-0123]).

The aim of our *in silico* analysis was to take the first step in the elucidation of the precise mechanism of the cyclin F (CCNF)-RRM2 axis in skin melanoma. The study aims to accelerate the development and to inspire other scientific teams to conduct similar research in the field.

In the present study, using the data available in the cBioPortal database, we showed for first time that high expression of cyclin F mRNA is associated with poorer prognosis in patients with skin cutaneous melanoma. Additionally, we present an overview of the molecular pathways involved in the cell cycle, cell death and DNA repair which are activated differentially in patients who exhibit high and low expression of cyclin F and RRM2.

Materials and methods
=====================

### Analysis of publicly available data

To assess the expression profile of cyclin F and RMM2 mRNA, we obtained data from The Cancer Genome Atlas via [www.cBioPortal.org](www.cBioPortal.org) ([@b10-or-40-01-0123]). Patients were divided into groups: with CCNF or RRM2 mRNA upregulated expression (z-score \>0) and with downregulated mRNA expression (z-score ≤0) and then, for each mRNA, we conducted overall survival and disease-free survival analysis. The same source was used for protein level comparison in patients with upregulated and downregulated cyclin F and RRM2 mRNA. In turn, we analyzed obtained information and used Reactome (<http://reactome.org>) and ToppGene Suite (<http://toppgene.cchmc.org>) to organize data into biological processes and functional molecular pathways.

### Statistical analysis

In the life span study of the melanoma patients, the data were analyzed with Kaplan-Meier survival analysis with included log-rank test for trend tests. Comparisons between groups expressing different levels of mRNA or proteins were conducted using Mann-Whitney U-test. All statistical analyses were performed using GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA, USA).

Results
=======

The TCGA data were used to characterize the prognostic value of cyclin F and RRM2 mRNA in melanoma. The results showed that increased expression of cyclin F mRNA is associated with worse outcome in melanoma patients ([Fig. 1](#f1-or-40-01-0123){ref-type="fig"}; [Tables I](#tI-or-40-01-0123){ref-type="table"} and [II](#tII-or-40-01-0123){ref-type="table"}). Median survival in patients with upregulated cyclin F was significantly lower (112.48 vs. 55.55 months; P\<0.0001). No significance in disease-free survival (DFS) was found. Furthermore, expression of RRM2 mRNA had a significant influence on median survival (102.04 vs. 61.47; P=0.034), but no effect on DSF was noted ([Fig. 2](#f2-or-40-01-0123){ref-type="fig"}; [Tables I](#tI-or-40-01-0123){ref-type="table"} and [II](#tII-or-40-01-0123){ref-type="table"}). Cyclin F significantly altered the expression of different cellular proteins. The expression of proteins negatively and positively correlated with CCNF mRNA are listed in [Tables III](#tIII-or-40-01-0123){ref-type="table"} and [V](#tV-or-40-01-0123){ref-type="table"}. Representative plots are shown in [Figs. 3](#f3-or-40-01-0123){ref-type="fig"} and [4](#f4-or-40-01-0123){ref-type="fig"}. Analogous data for RRM2 mRNA expression are shown in [Tables VII](#tVII-or-40-01-0123){ref-type="table"} and [IX](#tIX-or-40-01-0123){ref-type="table"}, and representative plots are presented in [Figs. 5](#f5-or-40-01-0123){ref-type="fig"} and [6](#f6-or-40-01-0123){ref-type="fig"}.

The analysis using Reactome showed that upregulation of cyclin F resulted in downregulation of pathways responsible for signal transduction and activation of cell cycle-related and DNA repair ([Fig. 7](#f7-or-40-01-0123){ref-type="fig"}). High expression of RRM2 mRNA also resulted in downregulation of cell signaling pathways. Activation of the cell cycle and DNA pathways was also visible but less univocal ([Fig. 8](#f8-or-40-01-0123){ref-type="fig"}). Upregulation of cyclin F coincides with altered expression of factors that were associated with worse patient outcome. Furthermore, patients with worse outcome had increased levels of proliferative proteins, such as cyclin E, cyclin B, PCNA, pro-survival factors such as p27 or FOXM1 and connected with AKT pathway activation (INPP4B). The list of biological processes altered by cyclin F dysregulation are presented in [Tables IV](#tIV-or-40-01-0123){ref-type="table"} and [VI](#tVI-or-40-01-0123){ref-type="table"}. Furthermore, data presenting biological processes influenced by changes in RRM2 expression are presented in [Tables VIII](#tVIII-or-40-01-0123){ref-type="table"} and [X](#tX-or-40-01-0123){ref-type="table"}.

Discussion
==========

There is only limited data describing cyclin F and its possible role in human cancer. D\'Angiolella *et al* characterized the functional axis which is responsible for DNA repair following genotoxic stress ([@b5-or-40-01-0123]). It is possible that interaction between cyclin F and RRM2 is significantly responsible for treatment response, thus detailed recognition of its nature may be useful for cancer clinical outcome prediction. Nuclear accumulation of RRM2, which allows efficient DNA repair, is preceded by downregulation of cyclin F. As it has been shown by D\'Angiolella *et al* the insertion of wild-type cyclin F into hTERT RPE-1 cells prevents transposition of RRM2 from the cytoplasm to the nucleus ([@b5-or-40-01-0123]). It has also been shown that overexpression of RRM2 may affect the proliferation of melanoma cells, their response to treatment *in vivo*, and is associated with worse overall survival in melanoma patients bearing mutations in the BRAF oncogene ([@b8-or-40-01-0123],[@b11-or-40-01-0123],[@b12-or-40-01-0123]). Based on these data, we hypothesized that low expression of cyclin F in melanoma patients can be related to a poorer prognosis. This hypothesis was strengthened by the fact that the relationship between low cyclin F expression and poorer prognosis was demonstrated by Fu *et al* in patients with hepatocellular carcinoma. They showed that downregulation of cyclin F in hepatocellular carcinoma tissue samples was related to larger tumor size and poor tumor differentiation ([@b13-or-40-01-0123]). Interestingly our analysis revealed that high expression of cyclin F mRNA is associated with poorer prognosis in skin cutaneous melanoma. Much as the result differs from what was expected, it is not surprising as overexpression of cyclin proteins is more common in cancer rather than their downregulation. Sun *et al* showed that overexpression of cyclin B1 is associated with poorer prognosis and reduced overall survival in breast cancer ([@b14-or-40-01-0123]). Li *et al* revealed an association between high expression of cyclin B1 and claudin-1 with worse outcome in patients with hypopharyngeal squamous cell carcinoma ([@b15-or-40-01-0123]). On the other hand, high cyclin B1 expression was found to reduce lymph node metastasis and distant metastasis stage, and was also associated with higher survival rates in colorectal cancer ([@b16-or-40-01-0123]). High expression of cyclin D1 is a poor prognostic factor in gastric, oropharyngeal and breast cancer ([@b17-or-40-01-0123]--[@b19-or-40-01-0123]). Additionally, the overexpression of cyclin E correlates with worse outcome in patients with breast cancer, rectal cancer and gastrointestinal cancer ([@b20-or-40-01-0123]--[@b22-or-40-01-0123]). Some evidence has shown that low expression of cyclin F may be tumorigenic. It has been proposed that the downregulation of cyclin F promotes centrosomal and mitotic abnormalities associated with impaired degradation of CP110, an important centriolar protein ([@b23-or-40-01-0123]). Moreover, cyclin F-mediated degradation of CDC-6 suppresses genome instability and prevents re-replication, limiting the number of cells with DNA content greater than 4N ([@b24-or-40-01-0123]). Pan *et al* showed that different levels of cyclin F, cyclin D and RBL1 between 2D and 3D cultured cells may be associated with radioresistance of cells in 3-dimensional culture. They noted that A549 cells cultured in 3D exhibited lower levels of cyclin F and were less susceptible to G2/M cell cycle arrest after X-ray irradiation ([@b25-or-40-01-0123]). However, the potential role of cyclin F as a tumor-promoting factor and the underlying mechanism remain elusive. The Oct4/NIPP1-CCNF/PP1 axis is responsible for maintenance of retinoblastoma protein 1 (Rb1) in the hyperphosphorylated state providing stem cell self-renewal and increased proliferation. Inactivation of Rb1 via CCNF/PP1 is also associated with enhanced ovarian cancer aggressiveness ([@b26-or-40-01-0123],[@b27-or-40-01-0123]). In our pathway analysis, we observed a decrease in the cell signaling-related pathway activity and increase in the cell cycle-related pathways in patients with upregulated levels of cyclin F. A recent report showed that cyclin F is a bridge between AKT kinase and cell cycle machinery. Choudhury *et al* hypothesized a model where growth signaling initiates a positive loop where AKT phosphorylates and stabilizes cyclin F in the SCF complex. This stabilization inhibits degradation of cyclin F via APC/C (Cdh1) complex and promotes SCF-dependent degradation of Cdh1. Degradation of Cdh1 is essential for S phase entry and loss of cyclin F impairs cell cycle progression ([@b28-or-40-01-0123],[@b29-or-40-01-0123]). Activation of the PI3K/AKT pathway is a common event in a variety of cancer diseases and it is believed to contribute to drug resistance. Although, we did not observe clear symptoms of PI3K/AKT activation, our analysis revealed downregulated INPP4B, tumor suppressor antagonizing PI3K/AKT pathway. Loss of INPP4B was found to increase AKT activation and drive higher proliferation rate and metastasis ([@b30-or-40-01-0123]). It has been also reported that a decreased level of INPP4B is releted to higher proliferative, invasive and metastatic potential of melanocytic neoplasms ([@b31-or-40-01-0123]). In contradiction to these reports is a study by Chi *et al* where upregulation of INPP4B in a melanoma subset was observed. Furthermore, INPP4B driven proliferation was Akt-independent and was mediated by serum- and glucocorticoid-regulated kinase 3 (SGK3). Additionally, they observed no significant differences between primary and metastatic melanoma suggesting the involvement of INPP4B in developing cancer from the early stages ([@b32-or-40-01-0123]).

In the present study, the upregulation of cyclin F mRNA was found to coincide with the downregulation of p27 protein, important cell cycle regulator involved in G1 arrest. Akman *et al* found that patients with melanoma are characterized by lower p27 expression in comparison to patients with benign nevi and dysplastic nevi ([@b33-or-40-01-0123]). Furthermore, Florenes *et al* reported that decreased expression of p27 is associated with increasing Breslow thickness and lower disease-free survival rates in primary nodular melanoma ([@b34-or-40-01-0123]). Additionally, the low expression of p27 in melanocytic lesions may be responsible for its high proliferation rate ([@b35-or-40-01-0123]). The lack of proper control in regards to cell cycle events is typical for cancer cells. As was mentioned in the introduction, the overexpression of cyclins is very common in various malignancies. In our analysis, elevated levels of cyclin F mRNA were also associated with upregulation of cyclin E1 and B1 proteins. Elevated levels of cyclin E1 were observed in melanoma and enhanced expression of cyclin E was noted in both primary and metastatic melanomas. In contrast, its overexpression was not observed in non-malignant nevi ([@b36-or-40-01-0123]). Bales *et al* reported that cyclin E is overexpressed in melanoma and present in the low-molecular form. Noteworthy, transfection of a primary cutaneous melanoma cell line with low tumorigenic and metastatic potential with low-molecular cyclin E forms resulted in the development of angiogenic tumors with prominent perineural invasion. Additionally, truncated forms of cyclin E triggered a dramatic increase in a number of metastasis events ([@b37-or-40-01-0123]). In turn, cyclin B1 is involved in proliferation and metastatic potential of melanoma cells ([@b38-or-40-01-0123]). Silencing of cyclin B exerts an antitumor effect on melanoma cells and lung metastases, both *in vitro* and *in vivo* ([@b39-or-40-01-0123]).

Kruiswijk *et al* reported that patients with elevated levels of cyclin B1, Pin1 and FOXM1 display a worse outcome and exhibit increased mortality ([@b40-or-40-01-0123]). FOXM1 is a pro-proliferative and pro-survival transcription factor participating in DNA repair. Moreover, these data are in agreement with our analysis, where a significant increase in FOXM1 protein in patients with upregulated cyclin F mRNA was noted. It suggests possible activation of cyclin F expression by FOXM1, but further research is needed to clarify this. Moreover, the upregulation of FOXM1 coincides with downregulation of FOXO3a. The abrogation of FOXO3a function was found to lead to increased tumor aggressiveness in melanoma and renal carcinoma ([@b41-or-40-01-0123],[@b42-or-40-01-0123]). Another important observation made in this study is that 4E-BP1 (4E binding protein 1) was hyperphosphorylated in patients with upregulated cyclin expression. Phosphorylation of 4E-BP1 results in dissociation from translation factor eIF4E and allows cap-dependent translation. Phospho-4E-BP1 may also be useful as a marker of mTOR pathway activity and integrates signals obtained from PI3K/AKT and RAS/RAF/MEK/ERK pathways ([@b43-or-40-01-0123]). Additionally, concomitant hyperphosphorylation of 4E-BP1 and activation of the PI3K/AKT pathway results in resistance to mTOR inhibitors. Moreover, in hypoxic conditions, 4E-BP1 initiates translation of proteins responsible for angiogenesis (VEGF-A), hypoxia response (HIF1α) and apoptosis resistance (Bcl-2) in advanced cancer ([@b44-or-40-01-0123],[@b45-or-40-01-0123]). Increased levels of phosphorylated 4E-BP1 are also associated with poor overall survival and significant difference in post-recurrence survival ([@b46-or-40-01-0123]). It is possible that cyclin F is a part of the specific cellular environment, promoting cell proliferation and survival.

The ability of cancer cells to efficiently repair DNA is a significant barrier to successful treatment. RRM2 is a part of the RNR and has been reported to be partially responsible for chemoresistance of cancer cells, including melanoma. However, our analysis did not reveal significant changes in overall survival or disease-free survival between patients with differential RRM2 mRNA expression. Aird *et al* showed that high RRM2 expression is correlated with worse outcome in melanoma patients ([@b8-or-40-01-0123]). Silencing of RRM2 inhibited melanoma growth which suggests the involvement of RRM2 in melanoma progression. Silencing of RRM2 and treatment with mutant BRAF inhibitor PLX4720 simultaneously and synergistically inhibited melanoma growth ([@b11-or-40-01-0123]). It is possible that the negative effect of RRM2 overexpression is limited to patients bearing BRAF^V600E^ mutation, but we cannot confirm this using TCGA data due to an insufficient number of patients with the BRAF mutation in the cohort.

Beyond controlling RRM2 levels, cyclin F is a limiting factor in histone H2.AX signalization. In the G2 phase cyclin F mediates degradation of SLBP protein which promotes synthesis of H2AFX mRNA. Presence of SLBP in the G2 phase increases H2.AX levels and makes the cell more susceptible to apoptosis under genotoxic stress. It is another piece of evidence showing how cyclin F promotes cancer progression ([@b47-or-40-01-0123]). Moreover, we observed an alteration in expression of other DNA-repair related proteins: XRCC1, PARP1, PCNA, and MSH6. All proteins were upregulated which is a hallmark of efficient DNA repair systems and a potential obstacle to successful treatment. However, the prognostic status of XRCC1 is ambiguous. Its overexpression is associated with less favorable prognosis in head and neck squamous carcinoma. Decreased levels of XRCC1 are responsible for acute side-effects after radiotherapy in breast cancer patients. Loss of XRCC1 confers a more aggressive phenotype in melanoma ([@b48-or-40-01-0123]--[@b50-or-40-01-0123]). It suggests an indirect effect of cyclin F overexpression on the DNA damage repair system. Additionally, PCNA in patients with upregulated cyclin F is very significantly increased, what confirms the higher proliferation potential of cells overexpressing cyclin F. These findings confirm a study by Wang *et al* in which treatment of cells with stimulatory polysaccharides from abalone, significantly increased the expression of cyclin B1, CDK1 and cyclin F ([@b51-or-40-01-0123]).

Another interesting observation was increased expression of TFRC (transferrin receptor 1) gene in patients with high expression of cyclin F and RRM2 mRNA. It has been reported that melanoma cells are able to upregulate transferrin receptor 1 through the hyaluronan/CD44 pathway. It is possible that this pathway promotes proliferation providing alternative iron supply for melanoma cells. High expression of TFRC is associated with unfavorable prognosis in breast and pancreatic cancer ([@b52-or-40-01-0123]--[@b54-or-40-01-0123]).

This newly discovered relationship between mRNA expression of CCNF and RRM2 provide and attractive point for further investigations in the field of dermato-oncology. Our analysis was performed using independent data obtained from TCGA and provide many key results that can be used in further explanation of the precise mechanisms. Moreover, we expect that the present results will be useful to other researchers and induce further investigations, essential for better diagnosis, prediction, therapy response, but also for better selection of patients for optimal therapy against skin melanoma. A high number of clones contributes to an exceptional level of intratumor heterogeneity of melanoma, but also refers to metastases which may originate from different subclones of the primary tumor. This creates an obstacle to proper diagnosis and successful treatment ([@b55-or-40-01-0123]). Increased research on the topic is needed for understanding the limitation or failure of contemporary therapies and the precise mechanism must and will be elucidated by our team *in vitro* in the immediate future using melanoma cancer cell panels. We suggest here to investigate the precise mechanism indicated in the study using all following cell lines: SK-MEL-1, A375, G-361, SK-MEL-3, SH-4, SK-MEL-24, RPMI-7951. However, we hope that the publication of *in silico* analyses accelerates the development and inspires other scientific teams to conduct similar research in the field.

In conclusion, the present study is a first attempt to elucidate the influence of cyclin F mRNA expression on the outcome of melanoma patients. High expression of cyclin F mRNA is associated with worse overall survival. Moreover, *in silico* analysis revealed that upregulated cyclin F mRNA expression is associated with activation of molecular pathways responsible for melanoma proliferation, metastatic potential and survival. These findings are a good starting point to address new cyclin F targets and interactions which drive the increased aggressiveness of the tumor.
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![(A, B, E and F) High expression of CCNF mRNA is associated with poorer prognosis in melanoma patients. Patients with melanoma were analyzed by Kaplan-Meier survival estimation (log-rank test). (C, D, G and H) Representative plots of patients with differential expression of CCNF mRNA: normalized (C and G) and z-score (D and H). OS, overall survival; DFS, disease-free survival; CCNF, cyclin F.](OR-40-01-0123-g00){#f1-or-40-01-0123}

![(A, B, E and F) High expression of RRM2 is associated with less favorable outcome in melanoma patients. Patients with melanoma were analyzed by Kaplan-Meier survival estimation (log-rank test). (C, D, G and H) Representative plots of patients with differential expression of RRM2: normalized (C and G) and z-score (D and H). OS, overall survival; DFS, disease-free survival; RRM2, ribonucleotide reductase family member 2.](OR-40-01-0123-g01){#f2-or-40-01-0123}

###### 

Dot plot representation of the protein levels by RPPA (z-score). (A-L) Proteins negatively correlated with CCNF mRNA. Horizontal bars represent lower quartile, median and higher quartile. CCNF, cyclin F; RPPA, reverse-phase protein array. Dot plot representation of the protein levels by RPPA (z-score). (M-AA) Proteins negatively correlated with CCNF mRNA. Horizontal bars represent lower quartile, median and higher quartile. CCNF, cyclin F; RPPA, reverse-phase protein array.
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###### 

Dot plot representation of the protein levels by RPPA (z-score). (A-S) Proteins positively correlated with CCNF mRNA. Horizontal bars represent lower quartile, median and higher quartile. CCNF, cyclin F; RPPA, reverse-phase protein array.
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###### 

Dot plot representation of the protein levels by RPPA (z-score). (A-P) Proteins negatively correlated with RRM2 mRNA. Horizontal bars represent lower quartile, median and higher quartile. RRM2, ribonucleotide reductase family member 2; RPPA, reverse-phase protein array.
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###### 

Dot plot representation of the protein levels by RPPA (z-score). (A-P) Proteins positively correlated with RRM2 mRNA. Horizontal bars represent lower quartile, median and higher quartile. RRM2, ribonucleotide reductase family member 2; RPPA, reverse-phase protein array.
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![(A) Pathways negatively correlated with CCNF expression. (B) Relationships between proteins negatively correlated with CCNF expression involved in pathway analysis. (C) Pathways positively correlated with CCNF expression. (D) Relationships between proteins positively correlated with CCNF expression. CCNF, cyclin F.](OR-40-01-0123-g11){#f7-or-40-01-0123}

![(A) Pathways negatively correlated with RRM2 expression. (B) Relationships between proteins negatively correlated with RRM2 expression involved in pathway analysis. (C) Pathways positively correlated with RRM2 expression. (D) Relationships between proteins positively correlated with RRM2 expression. RRM2, ribonucleotide reductase family member 2.](OR-40-01-0123-g12){#f8-or-40-01-0123}

###### 

Association of CCNF and RRM2 mRNA expression on the survival of melanoma patients.

                                                  Overall survival (%)   Disease-free survival (%)                           
  ------------------------------ -------- ------- ---------------------- --------------------------- ------- ------- ------- -------
  Total                          74.67    51.08   58.79                  39.20                       25.38   42.85   24.93   12.09
  CCNF expression (normalized)                                                                                               
    CCNF^low^                    113.44   55.49   68.40                  48.55                       35.00   46.05   24.17   15.40
    CCNF^medium^                 61.10    48.59   52.24                  34.64                       23.05   41.18   26.87   10.88
    CCNF^high^                   62.75    51.08   51.44                  30.36                       10.12   36.45   21.87   4.37
  CCNF expression (z-score)                                                                                                  
    CCNF^downregulated^          112.48   55.85   65.83                  47.57                       35.90   46.50   27.27   15.15
    CCNF^upregulated^            55.55    48.00   48.06                  27.93                       11.93   36.14   20.46   6.50
  RRM2 expression (normalized)                                                                                               
    RRM2^low^                    74.67    63.40   58.48                  42.51                       37.79   53.88   36.47   31.26
    RRM2^medium^                 94.91    58.97   64.07                  39.11                       21.44   49.07   22.17   10.57
    RRM2^high^                   65.83    47.60   55.55                  39.11                       23.47   37.74   24.46   8.74
  RRM2 expression (z-score)                                                                                                  
    RRM2^downregulated^          102.04   58.97   63.15                  41.44                       27.97   49.34   26.30   15.51
    RRM2^upregulated^            61.47    44.15   52.73                  37.40                       21.93   34.77   23.16   6.72

CCNF, cyclin F; RRM2, ribonucleotide reductase family member 2.

###### 

Changes in overall survival and disease-free survival as associated with CCNF and RRM2 mRNA expression in melanoma patients.

                                                Overall survival   Disease-free survival                                                      
  --------------------------------------------- ------------------ ----------------------- ---------- ---------- ------ ------------ -------- ----
  CCNF expression (normalized)                                                                                                                
    CCNF^low^ vs. total                         0.73               0.57--0.93              0.0119     \*         0.96   0.77--1.19   0.6915   NS
    CCNF^medium^ vs. total                      1.21               0.96--1.54              0.1070     NS         1.01   0.81--1.27   0.9072   NS
    CCNF^high^ vs. total                        1.33               0.90--1.97              0.1576     NS         1.11   0.75--1.62   0.6087   NS
    CCNF^low^ vs. CCNF^medium^                  0.60               0.45--0.80              0.0005     \*\*\*     0.95   0.73--1.27   0.6733   NS
    CCNF^low^ vs. CCNF^high^                    0.48               0.30--0.77              0.0022     \*\*       0.86   0.57--1.30   0.4748   NS
    CCNF^medium^ vs. CCNF^high^                 0.94               0.64--1.39              0.7717     NS         0.92   0.61--1.37   0.6784   NS
  CCNF expression (z-score)                                                                                                                   
    CCNF^downregulated^ vs. total               0.79               0.63--0.98              0.0317     \*         0.94   0.78--1.15   0.5671   NS
    CCNF^upregulated^ vs. total                 1.42               1.11--1.82              0.0053     \*\*       1.11   0.87--1.40   0.3980   NS
    CCNF^downregulated^ vs. CCNF^upregulated^   0.54               0.43--0.75              \<0.0001   \*\*\*\*   0.85   0.66--1.10   0.2211   NS
  RRM2 expression (normalized)                                                                                                                
    RRM2^low^ vs. total                         0.87               0.59--1.30              0.5052     NS         0.77   0.53--1.12   0.1693   NS
    RRM2^medium^ vs. total                      0.93               0.71--1.22              0.5970     NS         0.96   0.75--1.24   0.7756   NS
    RRM2^high^ vs. total                        0.95               0.76--1.17              0.6165     NS         1.08   0.88--1.32   0.4596   NS
    RRM2^low^ vs. RRM2^medium^                  1.10               0.68--1.76              0.7059     NS         1.31   0.85--2.03   0.2260   NS
    RRM2^low^ vs. RRM2^high^                    0.84               0.56--1.27              0.4156     NS         0.73   0.50--1.08   0.1134   NS
    RRM2^medium^ vs. RRM2^high^                 0.88               0.66--1.18              0.3845     NS         0.90   0.69--1.17   0.4161   NS
  RRM2 expression (z-score)                                                                                                                   
    RRM2^downregulated^ vs. total               0.88               0.71--1.09              0.2507     NS         1.11   0.91--1.36   0.3133   NS
    RRM2^upregulated^ vs. total                 1.17               0.92--1.50              0.1960     NS         1.15   0.92--1.44   0.2233   NS
    RRM2^downregulated^ vs. RRM2^upregulated^   0.75               0.57--0.98              0.0344     \*         0.78   0.61--1.00   0.0529   NS

HR, hazard ratio; CI, confidence interval; CCNF, cyclin F; RRM2, ribonucleotide reductase family member 2. \*\*\*\*, extremely significant (P\<0.0001); \*\*\*, extremely significant (P=0.0001 to 0.001); \*\*, very significant (P=0.001 to 0.01); \*, significant (P=0.01 to 0.05); NS, not significant (P≥0.05).

###### 

Expression of proteins which are negatively correlated with CCNF.

                             CCNF^downregulated^   CCNF^upregulated^              
  ---------------- --------- --------------------- ------------------- ---------- ----------
  A-Raf_pS299      ARAF      0.0567                −0.0105             0.0279     \*
  Annexin_VII      ANXA7     0.0085                −0.0491             0.0055     \*\*
  Annexin-1        ANXA1     0.2359                −0.0402             0.0006     \*\*\*
  AR               AR        0.0662                −0.0072             0.0380     \*
  Axl              AXL       0.1741                −0.0276             0.0283     \*
  Bak              BAK1      0.0059                −0.0199             0.5374     NS
  Bcl-2            BCL2      0.0461                −0.1069             0.0190     \*
  Bcl-xL           BCL2L1    0.0578                −0.0127             0.0609     NS
  Bim              BCL2L11   0.0081                −0.1046             0.0200     \*
  Caveolin-1       CAV1      0.2809                −0.0344             0.0013     \*\*
  CD31             PECAM1    0.0548                −0.0108             0.0260     \*
  CD49b            ITGA2     0.1129                −0.0100             \<0.0001   \*\*\*\*
  Chk1_pS345       CHEK1     0.0011                −0.0009             0.6241     NS
  DJ-1             PARK7     0.0503                −0.0112             0.0743     NS
  EGFR_pY1068      EGFR      0.0817                −0.0107             0.0015     \*\*
  ER-α             ESR1      0.0900                −0.0314             0.0002     \*\*\*
  FOXO3a           FOXO3     0.0724                −0.0102             \<0.0001   \*\*\*\*
  GATA3            GATA3     0.0186                −0.0356             0.0287     \*
  GATA6            GATA6     0.0949                −0.0295             0.0132     \*
  HER2             ERBB2     0.0678                −0.0827             0.0036     \*\*
  HER3             ERBB3     0.0023                −0.0620             0.2038     NS
  HER3_pY1289      ERBB3     0.0086                −0.0137             0.1953     NS
  INPP4B           INPP4B    0.0761                −0.0258             0.0008     \*\*\*
  JAB1             COPS5     0.0558                −0.1180             \<0.0001   \*\*\*\*
  JNK2             MAPK9     0.0404                −0.0589             0.0083     \*\*
  Myosin-IIa       MYH9      0.0003                −0.0030             0.9509     NS
  p27              CDKN1B    0.0582                −0.1027             \<0.0001   \*\*\*\*
  p38_pT180_Y182   MAPK14    0.0115                −0.0346             0.3252     NS
  p53              TP53      0.0557                −0.0223             0.0021     \*\*
  PARP_cleaved     PARP1     0.0227                −0.0241             0.0773     NS
  PDCD4            PDCD4     0.0854                −0.1255             0.0025     \*\*
  PEA15            PEA15     0.0238                −0.0052             0.4346     NS
  PI3K-p110-α      PIK3CA    0.0097                −0.0625             0.0315     \*
  PKC-α            PRKCA     0.1358                −0.2574             \<0.0001   \*\*\*\*
  PKC-α_pS657      PRKCA     0.1951                −0.1638             \<0.0001   \*\*\*\*
  PKC-δ_pS664      PRKCD     0.0194                −0.0539             0.1518     NS
  PRDX1            PRDX1     0.0266                −0.0393             0.2556     NS
  Rab25            RAB25     0.0432                −0.0767             0.0011     \*\*
  Rad50            RAD50     0.0579                −0.0170             0.1381     NS
  Shc_pY317        SHC1      0.0064                −0.0834             0.0026     \*\*
  Src_pY416        SRC       0.0296                −0.0103             0.4421     NS
  VEGFR2           KDR       0.0142                −0.0164             0.3048     NS

CCNF, cyclin F; RPPA, reverse-phase protein array. \*\*\*\*, extremely significant (P\<0.0001); \*\*\*, extremely significant (P=0.0001 to 0.001); \*\*, very significant (P=0.001 to 0.01); \*, significant (P=0.01 to 0.05); NS, not significant (P≥0.05).

###### 

Biological process and pathway analysis of genes whose products are negatively correlated with CCNF expression.

  Factor                                                        P-value    Number of genes   Gene list
  ------------------------------------------------------------- ---------- ----------------- ------------------------------------------------------------------------------------------------------------------------------
  Biological process                                                                         
    Regulation of apoptotic process                             1.26E-12   19                GATA3, GATA6, CDKN1B, FOXO3, PRKCA, ERBB2, BCL2, CAV1, MAPK9, BCL2L11, EGFR, PIK3CA, ANXA1, AXL, AR, ARAF, PDCD4, ESR1, TP53
    Regulation of intracellular signal transduction             7.99E-12   19                SHC1, GATA3, PRKCA, ERBB2, BCL2, CAV1, MAPK9, BCL2L11, EGFR, PIK3CA, COPS5, AXL, AR, ARAF, PDCD4, ESR1, INPP4B, TP53, PECAM1
    Apoptotic process                                           2.63E-11   19                GATA3, GATA6, CDKN1B, FOXO3, PRKCA, ERBB2, BCL2, CAV1, MAPK9, BCL2L11, EGFR, PIK3CA, ANXA1, AXL, AR, ARAF, PDCD4, ESR1, TP53
    Negative regulation of apoptotic process                    3.01E-11   15                GATA3, GATA6, CDKN1B, PRKCA, ERBB2, BCL2, CAV1, EGFR, PIK3CA, ANXA1, AXL, AR, ARAF, PDCD4, TP53
    Positive regulation of cellular protein metabolic process   1.08E-10   17                SHC1, GATA3, CDKN1B, PRKCA, ERBB2, BCL2, ITGA2, CAV1, MAPK9, BCL2L11, EGFR, PIK3CA, AR, ARAF, ESR1, TP53, PECAM1
    Regulation of protein modification process                  1.30E-10   18                SHC1, GATA3, CDKN1B, PRKCA, ERBB2, BCL2, ITGA2, CAV1, MAPK9, EGFR, PIK3CA, COPS5, AR, ARAF, PDCD4, ESR1, TP53, PECAM1
    Positive regulation of signaling                            3.37E-10   17                SHC1, GATA3, GATA6, PRKCA, ERBB2, BCL2, ITGA2, CAV1, MAPK9, BCL2L11, EGFR, AXL, AR, ARAF, ESR1, TP53, PECAM1
    Positive regulation of cell communication                   3.61E-10   17                SHC1, GATA3, GATA6, PRKCA, ERBB2, BCL2, ITGA2, CAV1, MAPK9, BCL2L11, EGFR, AXL, AR, ARAF, ESR1, TP53, PECAM1
    Regulation of phosphorylation                               7.58E-10   16                SHC1, CDKN1B, PRKCA, ERBB2, BCL2, CAV1, MAPK9, EGFR, PIK3CA, COPS5, AR, ARAF, PDCD4, ESR1, TP53, PECAM1
    Positive regulation of phosphorylation                      7.76E-10   14                SHC1, CDKN1B, PRKCA, ERBB2, BCL2, CAV1, MAPK9, EGFR, PIK3CA, AR, ARAF, ESR1, TP53, PECAM1
    Regulation of cell proliferation                            2.67E-09   16                SHC1, GATA3, GATA6, CDKN1B, FOXO3, PRKCA, ERBB2, BCL2, RAB25, ITGA2, CAV1, EGFR, ANXA1, AR, ESR1, TP53
    Positive regulation of cell proliferation                   4.30E-09   13                SHC1, GATA6, CDKN1B, PRKCA, ERBB2, BCL2, RAB25, ITGA2, CAV1, EGFR, ANXA1, AR, ESR1
    Cell adhesion                                               1.11E-07   14                SHC1, GATA3, PRKCA, ERBB2, BCL2, ITGA2, CAV1, BCL2L11, EGFR, PIK3CA, ANXA1, AXL, TP53, PECAM1
    Positive regulation of apoptotic process                    3.01E-07   10                GATA6, CDKN1B, FOXO3, BCL2, CAV1, MAPK9, BCL2L11, ANXA1, PDCD4, TP53
  Pathway                                                                                    
    EGFR tyrosine kinase inhibitor resistance                   2.50E-13   10                SHC1, FOXO3, PRKCA, ERBB2, BCL2, BCL2L11, EGFR, PIK3CA, AXL, ARAF
    Endocrine resistance                                        9.60E-13   10                SHC1, CDKN1B, ERBB2, BCL2, MAPK9, EGFR, PIK3CA, ARAF, ESR1, TP53
    Proteoglycans in cancer                                     1.01E-09   10                PRKCA, ERBB2, ITGA2, CAV1, EGFR, PIK3CA, ARAF, PDCD4, ESR1, TP53
    ErbB signaling pathway                                      1.01E-09   8                 SHC1, CDKN1B, PRKCA, ERBB2, MAPK9, EGFR, PIK3CA, ARAF
    Focal adhesion                                              1.57E-08   9                 SHC1, PRKCA, ERBB2, BCL2, ITGA2, CAV1, MAPK9, EGFR, PIK3CA
    Pathways in cancer                                          1.57E-08   11                CDKN1B, PRKCA, ERBB2, BCL2, ITGA2, MAPK9, EGFR, PIK3CA, AR, ARAF, TP53
    MicroRNAs in cancer                                         2.01E-08   10                SHC1, CDKN1B, PRKCA, ERBB2, BCL2, BCL2L11, EGFR, PIK3CA, PDCD4, TP53
    FoxO signaling pathway                                      4.15E-07   7                 CDKN1B, FOXO3, MAPK9, BCL2L11, EGFR, PIK3CA, ARAF
    Signaling by SCF-KIT                                        7.61E-07   9                 SHC1, CDKN1B, FOXO3, PRKCA, ERBB2, EGFR, PIK3CA, ARAF, TP53
    PI3K-Akt signaling pathway                                  7.61E-07   9                 CDKN1B, FOXO3, PRKCA, BCL2, ITGA2, BCL2L11, EGFR, PIK3CA, TP53
    Signaling by NGF                                            9.31E-07   10                SHC1, CDKN1B, FOXO3, PRKCA, ERBB2, BCL2L11, EGFR, PIK3CA, ARAF, TP53
    HIF-1 signaling pathway                                     1.43E-06   6                 CDKN1B, PRKCA, ERBB2, BCL2, EGFR, PIK3CA
    Apoptosis signaling pathway                                 1.43E-06   6                 PRKCA, BCL2, MAPK9, BCL2L11, PIK3CA, TP53
    Signaling by ERBB2                                          1.54E-06   5                 SHC1, PRKCA, ERBB2, EGFR, PIK3CA

CCNF, cyclin F; SCF, Skp, Cullin, F-box containing. P-values were corrected for multiple comparisons using the false discovery rate (FDR) (Benjamini and Hochberg).

###### 

Expression of proteins which positively correlate with CCNF.

                               CCNF^downregulated^   CCNF^upregulated^              
  ----------------- ---------- --------------------- ------------------- ---------- ----------
  4E-BP1            EIF4EBP1   −0.0327               0.0285              0.3383     NS
  4E-BP1_pS65       EIF4EBP1   −0.0677               0.0891              \<0.0001   \*\*\*\*
  4E-BP1_pT70       EIF4EBP1   −0.0655               0.0860              \<0.0001   \*\*\*\*
  ACC_pS79          ACACA      −0.0054               0.0362              0.3200     NS
  C-Raf             RAF1       −0.0110               0.0031              0.3485     NS
  CDK1_pY15         CDK1       −0.1318               0.1145              \<0.0001   \*\*\*\*
  Chk1              CHEK1      −0.0156               0.0301              0.0333     \*
  Chk2              CHEK2      −0.0137               0.0578              0.0421     \*
  Cyclin_B1         CCNB1      −0.2619               0.2546              \<0.0001   \*\*\*\*
  Cyclin_E1         CCNE1      −0.0766               0.1020              0.0009     \*\*\*
  eEF2              EEF2       −0.0851               0.0434              0.0449     \*
  FoxM1             FOXM1      −0.0423               0.1525              \<0.0001   \*\*\*\*
  GAPDH             GAPDH      −0.0492               0.0336              0.5952     NS
  MIG-6             ERRFI1     −0.0025               0.0536              0.1141     NS
  MSH2              MSH2       −0.0296               0.0032              0.3485     NS
  MSH6              MSH6       −0.1614               0.0359              0.0003     \*\*\*
  NF-kB-p65_pS536   NFKB1      −0.0494               0.0028              0.6642     NS
  NF2               NF2        −0.0131               0.0148              0.7265     NS
  p21               CDKN1A     −0.0769               0.0860              0.0186     \*
  p38_MAPK          MAPK14     −0.0104               0.0141              0.7464     NS
  p62-LCK-ligand    SQSTM1     −0.0667               0.0042              0.1143     NS
  PARP1             PARP1      −0.0340               0.1803              0.0425     \*
  PCNA              PCNA       −0.0654               0.1086              \<0.0001   \*\*\*\*
  PRAS40_pT246      AKT1S1     −0.0248               0.0148              0.1293     NS
  Rb_pS807_S811     RB1        −0.1385               0.1091              0.0014     \*\*
  S6_pS240_S244     RPS6KB1    −0.0474               0.1577              0.0086     \*\*
  SLC1A5            SLC1A5     −0.0542               0.0092              0.2129     NS
  Src               SRC        −0.0137               0.0101              0.4254     NS
  Src_pY527         SRC        −0.0814               0.1241              0.0022     \*\*
  TFRC              TFRC       −0.1894               0.3049              \<0.0001   \*\*\*\*
  Tuberin_pT1462    TSC2       −0.0626               0.0410              0.0488     \*
  XRCC1             XRCC1      −0.0784               0.0078              0.0065     \*\*

CCNF, cyclin F; RPPA, reverse-phase protein array. \*\*\*\*, extremely significant (P\<0.0001); \*\*\*, extremely significant (P=0.0001 to 0.001); \*\*, very significant (P=0.001 to 0.01); \*, significant (P=0.01 to 0.05); NS, not significant (P≥0.05).

###### 

Biological process and pathway analysis of genes whose products are positively correlated with CCNF expression.

  Factor                                                           P-value    Number of genes   Gene list
  ---------------------------------------------------------------- ---------- ----------------- ------------------------------------------------------------------------------------------
  Biological process                                                                            
    Regulation of cell cycle                                       1.88E-10   13                CHEK2, FOXM1, CCNE1, CDKN1A, RB1, TSC2, RPS6KB1, CDK1, CHEK1, PCNA, EIF4EBP1, SRC, CCNB1
    Cell cycle phase transition                                    1.94E-10   11                CHEK2, FOXM1, CCNE1, CDKN1A, RB1, RPS6KB1, CDK1, CHEK1, PCNA, EIF4EBP1, CCNB1
    Cell cycle G1/S phase transition                               2.22E-10   9                 CHEK2, CCNE1, CDKN1A, RB1, RPS6KB1, CDK1, PCNA, EIF4EBP1, CCNB1
    Positive regulation of cell cycle                              1.82E-09   9                 CHEK2, CDKN1A, RB1, RPS6KB1, CDK1, PCNA, EIF4EBP1, SRC, CCNB1
    Regulation of DNA metabolic process                            2.32E-09   9                 CHEK2, FOXM1, CDKN1A, MSH6, PARP1, CDK1, CHEK1, PCNA, SRC
    Cell cycle arrest                                              4.10E-09   8                 CHEK2, FOXM1, CDKN1A, RB1, TSC2, CDK1, PCNA, CCNB1
    Negative regulation of mitotic cell cycle phase transition     8.06E-09   7                 CHEK2, CDKN1A, RB1, CDK1, CHEK1, PCNA, CCNB1
    Negative regulation of G1/S transition of mitotic cell cycle   2.07E-08   6                 CHEK2, CDKN1A, RB1, CDK1, PCNA, CCNB1
    DNA damage checkpoint                                          1.70E-07   6                 CHEK2, CDKN1A, CDK1, CHEK1, PCNA, CCNB1
    Positive regulation of macromolecule biosynthetic process      1.94E-07   12                CHEK2, FOXM1, CCNE1, RB1, PARP1, TSC2, EEF2, RPS6KB1, CDK1, CHEK1, PCNA, SRC
    DNA repair                                                     3.08E-07   8                 CHEK2, FOXM1, MSH6, PARP1, CDK1, CHEK1, PCNA, XRCC1
    Positive regulation of gene expression                         3.21E-07   12                CHEK2, FOXM1, CCNE1, RB1, PARP1, TSC2, EEF2, RPS6KB1, CDK1, CHEK1, SRC, CCNB1
    Positive regulation of cell cycle arrest                       3.74E-07   5                 CHEK2, CDKN1A, CDK1, PCNA, CCNB1
    Positive regulation of cellular biosynthetic process           3.74E-07   12                CHEK2, FOXM1, CCNE1, RB1, PARP1, TSC2, EEF2, RPS6KB1, CDK1, CHEK1, PCNA, SRC
  Pathway                                                                                       
    Cell cycle                                                     1.06E-09   8                 CHEK2, CCNE1, CDKN1A, RB1, CDK1, CHEK1, PCNA, CCNB1
    p53 signaling pathway                                          1.06E-09   7                 CHEK2, CCNE1, CDKN1A, TSC2, CDK1, CHEK1, CCNB1
    FOXM1 transcription factor network                             1.61E-09   6                 CHEK2, FOXM1, RB1, CDK1, CCNB1, XRCC1
    E2F mediated regulation of DNA replication                     9.24E-08   5                 CCNE1, RB1, CDK1, PCNA, CCNB1
    mTOR signaling pathway                                         9.46E-07   5                 CCNE1, TSC2, EEF2, RPS6KB1, EIF4EBP1
    ATM signaling pathway                                          4.84E-05   3                 CHEK2, CDKN1A, CHEK1
    DNA double-strand break repair                                 5.32E-05   5                 CHEK2, PARP1, CHEK1, PCNA, XRCC1
    ErbB signaling pathway                                         8.14E-05   4                 CDKN1A, RPS6KB1, EIF4EBP1, SRC
    Endocrine resistance                                           1.16E-04   4                 CDKN1A, RB1, RPS6KB1, SRC
    HIF-1 signaling pathway                                        1.39E-04   4                 CDKN1A, RPS6KB1, EIF4EBP1, TFRC
    Base excision repair                                           1.57E-04   3                 PARP1, PCNA, XRCC1
    AMPK signaling pathway                                         2.39E-04   4                 TSC2, EEF2, RPS6KB1, EIF4EBP1
    PI3K-Akt signaling pathway                                     7.78E-04   5                 CCNE1, CDKN1A, TSC2, RPS6KB1, EIF4EBP1
    Mismatch repair                                                1.42E-03   2                 MSH6, PCNA

CCNF, cyclin F. P-values were corrected for multiple comparisons using the false discovery rate (FDR) (Benjamini and Hochberg).

###### 

Expression of proteins which are negatively correlated with RRM2.

                            RRM2^downregulated^   RRM2^upregulated^              
  ---------------- -------- --------------------- ------------------- ---------- ----------
  14-3-3_ζ         YWHAZ    0.0436                −0.0176             0.1293     NS
  α-catenin        CTNNB1   0.0676                −0.0037             0.0957     NS
  AMPK_α           PRKAA1   0.0076                −0.0467             0.0311     \*
  Bcl-2            BCL2     0.1080                −0.1967             \<0.0001   \*\*\*\*
  cIAP             BIRC2    0.0042                −0.0600             0.0043     \*\*
  E-cadherin       CDH1     0.1282                −0.4331             0.0003     \*\*\*
  ER-α             ESR1     0.0796                −0.0194             0.0013     \*\*
  FOXO3a           FOXO3    0.0664                −0.0035             0.0041     \*\*
  GATA3            GATA3    0.0059                −0.0189             0.0886     NS
  HER2             ERBB2    0.0414                −0.0487             0.0298     \*
  HER3             ERBB3    0.0900                −0.1863             \<0.0001   \*\*\*\*
  INPP4B           INPP4B   0.0749                −0.0261             0.0007     \*\*\*
  JAB1             COPS5    0.0083                −0.0772             0.0957     NS
  JNK2             MAPK9    0.0047                −0.0109             0.6772     NS
  p27_pT198        CDKN1B   0.0017                −0.0069             0.7788     NS
  p38_MAPK         MAPK14   0.0349                −0.0488             0.0165     \*
  p38_pT180_Y182   MAPK14   0.0086                −0.0314             0.4440     NS
  PARP_cleaved     PARP1    0.0073                −0.0035             0.4065     NS
  PDCD4            PDCD4    0.1225                −0.1818             0.0001     \*\*\*
  PDK1             PDPK1    0.0294                −0.0014             0.1348     NS
  PDK1_pS241       PDPK1    0.0071                −0.0442             0.2341     NS
  PI3K-p85         PIK3R1   0.0116                −0.0613             0.0605     NS
  PKC-α            PRKCA    0.0155                −0.0969             0.0414     \*
  PKC-α_pS657      PRKCA    0.0906                −0.0247             0.0307     \*
  PRDX1            PRDX1    0.0146                −0.0238             0.5525     NS
  PREX1            PREX1    0.0619                −0.0082             0.2623     NS
  Rab25            RAB25    0.0707                −0.1177             \<0.0001   \*\*\*\*
  Rad50            RAD50    0.0570                −0.0174             0.0624     NS
  Src              SRC      0.0459                −0.0729             0.0033     \*\*
  Src_pY527        SRC      0.0315                −0.0300             0.3020     NS
  VEGFR2           KDR      0.0191                −0.0239             0.4077     NS
  YAP              YAP1     0.0412                −0.0283             0.0215     \*
  YAP_pS127        YAP1     0.1242                −0.0491             0.0106     \*

RRM2, ribonucleotide reductase family member 2; RPPA, reverse-phase protein array. \*\*\*\*, extremely significant (P\<0.0001); \*\*\*, extremely significant (P=0.0001 to 0.001); \*\*, very significant (P=0.001 to 0.01); \*, significant (P=0.01 to 0.05); NS, not significant (P≥0.05).

###### 

Biological process and pathway analysis of genes whose products are negatively correlated with RRM2 expression.

  Factor                                                       P-value    Number of genes   Gene list
  ------------------------------------------------------------ ---------- ----------------- ---------------------------------------------------------------------------------------
  Biological process                                                                        
    Regulation of cell proliferation                           4.03E-09   13                FOXO3, CDH1, BIRC2, PRKCA, YAP1, ERBB2, ERBB3, ESR1, BCL2, RAB25, MAPK14, PRKAA1, SRC
    Apoptotic process                                          1.03E-08   13                FOXO3, CDH1, BIRC2, PRKCA, YAP1, ERBB2, ERBB3, PDCD4, ESR1, BCL2, MAPK14, PRKAA1, SRC
    Regulation of apoptotic process                            1.39E-08   12                FOXO3, CDH1, BIRC2, PRKCA, YAP1, ERBB2, ERBB3, PDCD4, ESR1, BCL2, PRKAA1, SRC
    Negative regulation of signal transduction                 2.30E-08   11                FOXO3, CDH1, PRKCA, YAP1, ERBB3, PDCD4, ESR1, BCL2, MAPK14, PRKAA1, SRC
    Negative regulation of apoptotic process                   8.07E-07   9                 BIRC2, PRKCA, YAP1, ERBB2, ERBB3, PDCD4, BCL2, PRKAA1, SRC
    Regulation of intracellular signal transduction            8.07E-07   11                BIRC2, PRKCA, ERBB2, ERBB3, PDCD4, ESR1, BCL2, INPP4B, MAPK14, PRKAA1, SRC
    Positive regulation of intracellular signal transduction   1.09E-06   9                 BIRC2, PRKCA, ERBB2, ERBB3, ESR1, BCL2, MAPK14, PRKAA1, SRC
    Regulation of cell motility                                4.00E-06   8                 CDH1, PRKCA, ERBB2, ERBB3, BCL2, RAB25, MAPK14, SRC
    Positive regulation of protein modification process        5.45E-06   9                 BIRC2, PRKCA, ERBB2, ERBB3, ESR1, BCL2, MAPK14, PRKAA1, SRC
    Regulation of cellular component movement                  6.29E-06   8                 CDH1, PRKCA, ERBB2, ERBB3, BCL2, RAB25, MAPK14, SRC
    MAPK cascade                                               8.78E-06   8                 PRKCA, ERBB2, ERBB3, PDCD4, ESR1, MAPK14, PRKAA1, SRC
    Positive regulation of protein phosphorylation             1.03E-05   8                 PRKCA, ERBB2, ERBB3, ESR1, BCL2, MAPK14, PRKAA1, SRC
    Signal transduction by protein phosphorylation             1.03E-05   8                 PRKCA, ERBB2, ERBB3, PDCD4, ESR1, MAPK14, PRKAA1, SRC
    Regulation of canonical Wnt signaling pathway              3.05E-05   5                 FOXO3, CDH1, YAP1, MAPK14, SRC
  Pathway                                                                                   
    EGFR tyrosine kinase inhibitor resistance                  1.74E-07   6                 FOXO3, PRKCA, ERBB2, ERBB3, BCL2, SRC
    Proteoglycans in cancer                                    5.39E-07   7                 PRKCA, ERBB2, ERBB3, PDCD4, ESR1, MAPK14, SRC
    a6b1 and a6b4 Integrin signaling                           9.50E-06   4                 CDH1, PRKCA, ERBB2, ERBB3
    Endocrine resistance                                       1.17E-05   5                 ERBB2, ESR1, BCL2, MAPK14, SRC
    Signaling by ERBB2                                         4.47E-05   4                 PRKCA, ERBB2, ERBB3, SRC
    Focal adhesion                                             2.06E-04   5                 BIRC2, PRKCA, ERBB2, BCL2, SRC
    ErbB signaling pathway                                     2.06E-04   4                 PRKCA, ERBB2, ERBB3, SRC
    NGF signalling via TRKA from the plasma membrane           2.42E-04   6                 FOXO3, PRKCA, ERBB2, ERBB3, MAPK14, SRC
    FAS (CD95) signaling pathway                               4.38E-04   3                 BIRC2, MAPK14, SRC
    Signalling by NGF                                          4.82E-04   6                 FOXO3, PRKCA, ERBB2, ERBB3, MAPK14, SRC
    PI3K/AKT activation                                        4.82E-04   4                 FOXO3, ERBB2, ERBB3, SRC
    Cadherin signaling pathway                                 6.77E-04   4                 CDH1, ERBB2, ERBB3, SRC
    Pathways in cancer                                         1.04E-03   5                 CDH1, BIRC2, PRKCA, ERBB2, BCL2
    Signaling by SCF-KIT                                       6.93E-04   5                 FOXO3, PRKCA, ERBB2, ERBB3, SRC

RRM2, ribonucleotide reductase family member 2. P-values were corrected for multiple comparisons using the false discovery rate (FDR) (Benjamini and Hochberg).

###### 

Expression of proteins which are positively correlated with RRM2.

                                RRM2^downregulated^   RRM2^upregulated^              
  ------------------ ---------- --------------------- ------------------- ---------- ----------
  4E-BP1             EIF4EBP1   −0.0824               0.0995              0.0010     \*\*\*
  4E-BP1_pS65        EIF4EBP1   −0.0413               0.0554              0.0126     \*
  4E-BP1_pT70        EIF4EBP1   −0.0152               0.0185              0.2779     NS
  ACC_pS79           ACACA      −0.0209               0.0587              0.0782     NS
  ACC1               ACACA      −0.0340               0.1352              0.0024     \*\*
  Bax                BAX        −0.0251               0.0043              0.8262     NS
  C-Raf              RAF1       −0.0244               0.0222              0.0089     \*\*
  CDK1_pY15          CDK1       −0.0711               0.0147              0.1638     NS
  Chk1               CHEK1      −0.0460               0.0737              \<0.0001   \*\*\*\*
  Chk1_pS345         CHEK1      −0.0142               0.0205              0.0618     NS
  Chk2               CHEK2      −0.0412               0.0977              0.0002     \*\*\*
  Cyclin_B1          CCNB1      −0.2434               0.2391              \<0.0001   \*\*\*\*
  Cyclin_E1          CCNE1      −0.0330               0.0445              0.1473     NS
  eEF2               EEF2       −0.0765               0.0339              0.1272     NS
  EGFR_pY1173        EGFR       −0.0088               0.0283              0.1524     NS
  eIF4E              EIF4E      −0.0487               0.0033              0.1951     NS
  FoxM1              FOXM1      −0.0608               0.1823              \<0.0001   \*\*\*\*
  GAPDH              GAPDH      −0.0538               0.0416              0.0996     NS
  HER3_pY1289        ERBB3      −0.0062               0.0066              0.3676     NS
  MSH2               MSH2       −0.0493               0.0314              0.0703     NS
  MSH6               MSH6       −0.1812               0.0677              \<0.0001   \*\*\*\*
  Myosin-IIa         MYH9       −0.0317               0.0371              0.4099     NS
  NF2                NF2        −0.0205               0.0258              0.2552     NS
  p21                CDKN1A     −0.0880               0.1049              0.0025     \*\*
  p62-LCK-ligand     SQSTM1     −0.0850               0.0313              0.1070     NS
  p90RSK             RPS6KA1    −0.0133               0.0750              0.0363     \*
  PCNA               PCNA       −0.0499               0.0905              0.0001     \*\*\*
  PRAS40_pT246       AKT1S1     −0.0225               0.0124              0.3327     NS
  Rb_pS807_S811      RB1        −0.1222               0.0913              0.0035     \*\*
  S6_pS235_S236      RPS6KB1    −0.0110               0.2044              0.0053     \*\*
  S6_pS240_S244      RPS6KB1    −0.0516               0.1676              0.0024     \*\*
  SLC1A5             SLC1A5     −0.0858               0.0421              0.0743     NS
  Src_pY416          SRC        −0.0307               0.0735              0.0630     NS
  TFRC               TFRC       −0.1404               0.2463              0.0007     \*\*\*
  Transglutaminase   TGM1       −0.0275               0.0094              0.5674     NS
  TSC1               TSC1       −0.0611               0.0051              0.1200     NS

RRM2, ribonucleotide reductase family member 2; RPPA, reverse-phase protein array. \*\*\*\*, extremely significant (P\<0.0001); \*\*\*, extremely significant (P=0.0001 to 0.001); \*\*, very significant (P=0.001 to 0.01); \*, significant (P=0.01 to 0.05); NS, not significant (P≥0.05).

###### 

Biological process and pathway analysis of genes whose products are positively correlated with RRM2 expression.

  Factor                                                                 P-value    Number of genes   Gene list
  ---------------------------------------------------------------------- ---------- ----------------- ---------------------------------------------------------------------------------
  Biological process                                                                                  
    Cell cycle phase transition                                          1.99E-08   9                 CHEK2, FOXM1, CDKN1A, RB1, RPS6KB1, CHEK1, PCNA, EIF4EBP1, CCNB1
    Cell cycle G1/S phase transition                                     9.08E-08   7                 CHEK2, CDKN1A, RB1, RPS6KB1, PCNA, EIF4EBP1, CCNB1
    Negative regulation of cell cycle phase transition                   1.97E-07   6                 CHEK2, CDKN1A, RB1, CHEK1, PCNA, CCNB1
    Cell cycle                                                           1.97E-07   11                CHEK2, FOXM1, CDKN1A, RB1, MSH6, RPS6KA1, RPS6KB1, CHEK1, PCNA, EIF4EBP1, CCNB1
    Positive regulation of cell cycle                                    2.96E-07   7                 CHEK2, CDKN1A, RB1, RPS6KB1, PCNA, EIF4EBP1, CCNB1
    Cell cycle process                                                   3.83E-07   10                CHEK2, FOXM1, CDKN1A, RB1, MSH6, RPS6KB1, CHEK1, PCNA, EIF4EBP1, CCNB1
    Regulation of cell cycle                                             5.63E-07   9                 CHEK2, FOXM1, CDKN1A, RB1, RPS6KB1, CHEK1, PCNA, EIF4EBP1, CCNB1
    Negative regulation of cell cycle G1/S phase transition              5.94E-07   5                 CHEK2, CDKN1A, RB1, PCNA, CCNB1
    Regulation of cell cycle arrest                                      7.05E-07   5                 CHEK2, FOXM1, CDKN1A, PCNA, CCNB1
    Signal transduction by p53 class mediator                            1.11E-06   6                 CHEK2, FOXM1, CDKN1A, CHEK1, PCNA, CCNB1
    Signal transduction in response to DNA damage                        1.11E-06   5                 CHEK2, FOXM1, CDKN1A, PCNA, CCNB1
    DNA integrity checkpoint                                             3.58E-06   5                 CHEK2, CDKN1A, CHEK1, PCNA, CCNB1
    Regulation of cell proliferation                                     1.36E-04   8                 FOXM1, CDKN1A, RB1, RAF1, RPS6KB1, CHEK1, CCNB1, TFRC
    Regulation of cell growth                                            2.26E-04   5                 FOXM1, CDKN1A, RB1, RPS6KA1, TFRC
  Pathway                                                                                             
    Cell cycle                                                           6.87E-07   6                 CHEK2, CDKN1A, RB1, CHEK1, PCNA, CCNB1
    Insulin signalling                                                   9.14E-06   4                 RAF1, RPS6KA1, RPS6KB1, EIF4EBP1
    FOXM1 transcription factor network                                   9.14E-06   4                 CHEK2, FOXM1, RB1, CCNB1
    mTOR signaling pathway                                               5.69E-05   4                 RAF1, RPS6KA1, RPS6KB1, EIF4EBP1
    p53 signaling pathway                                                6.70E-05   4                 CHEK2, CDKN1A, CHEK1, CCNB1
    ATM signaling pathway                                                9.01E-05   3                 CHEK2, CDKN1A, CHEK1
    ErbB signaling pathway                                               1.04E-04   4                 CDKN1A, RAF1, RPS6KB1, EIF4EBP1
    HIF-1 signaling pathway                                              1.53E-04   4                 CDKN1A, RPS6KB1, EIF4EBP1, TFRC
    E2F mediated regulation of DNA replication                           2.21E-04   3                 RB1, PCNA, CCNB1
    G2/M DNA damage checkpoint                                           2.21E-04   2                 CHEK1, CCNB1
    G1/S Transition                                                      2.34E-04   4                 CDKN1A, RB1, PCNA, CCNB1
    EGFR tyrosine kinase inhibitor resistance                            1.20E-03   3                 RAF1, RPS6KB1, EIF4EBP1
    RB tumor suppressor/checkpoint signaling in response to DNA damage   1.25E-03   2                 RB1, CHEK1
    MAPKinase signaling pathway                                          1.49E-03   3                 RAF1, RPS6KA1, RPS6KB1

RRM2, ribonucleotide reductase family member 2. P-values were corrected for multiple comparisons using the false discovery rate (FDR (Benjamini and Hochberg).
